Cannonball72
GLP-1 Apprentice

How Much Muscle Are GLP-1 Patients Actually Losing?
Two systematic reviews. One question. Different answers.
substance-over-noise.beehiiv.com
GLP-1s and Muscle Loss: What the Evidence Actually Shows
Two 2026 systematic reviews appear to conflict: one found absolute lean mass losses of only 1–4%, while the other found 68% of GLP-1 interventions exceeded the benchmark of losing more than 25% of total weight as muscle. They’re answering different questions — one tracks absolute LBM change from baseline, the other tracks lean mass as a proportion of total weight lost.  Crucially, the comparator data undercuts the alarm: among lifestyle/placebo arms, 50% of interventions also exceeded the muscle-loss benchmark at a median weight loss of just ~2.4%. 
The ratio isn’t unique to GLP-1s — the drugs just produce more weight loss.
The “lean mass loss” signal itself is likely overstated due to DXA’s limitations. DXA cannot distinguish skeletal muscle from liver mass, intramuscular fat, glycogen, or extracellular fluid — and Langer et al. found liver mass decreased 20–55% across incretin agents in preclinical models, tracking tightly with body weight while muscle mass barely did.  When function is actually measured, semaglutide reduced muscle cross-sectional area on ultrasound yet grip strength and knee extension were unchanged; STEP 9 showed improved physical function scores despite lean mass changes.  Mass and function are dissociable — and often moving in opposite directions.
The practical answer is clear. The Lundgren NEJM RCT showed that exercise plus liraglutide preserved lean mass and produced 15.7% total weight loss — roughly double the fat reduction of either intervention alone — while neutralizing liraglutide’s resting heart rate increase. A small case series with structured resistance training on semaglutide/tirzepatide showed two of three patients actually gaining lean tissue during major weight loss. The protocol: resistance training 2–3x/week, protein at 1.2–1.6 g/kg adjusted body weight, and functional monitoring (grip strength, gait speed) — built in from the start.
Two systematic reviews. One question. Different answers.
substance-over-noise.beehiiv.com
GLP-1s and Muscle Loss: What the Evidence Actually Shows
Two 2026 systematic reviews appear to conflict: one found absolute lean mass losses of only 1–4%, while the other found 68% of GLP-1 interventions exceeded the benchmark of losing more than 25% of total weight as muscle. They’re answering different questions — one tracks absolute LBM change from baseline, the other tracks lean mass as a proportion of total weight lost.  Crucially, the comparator data undercuts the alarm: among lifestyle/placebo arms, 50% of interventions also exceeded the muscle-loss benchmark at a median weight loss of just ~2.4%. 
The ratio isn’t unique to GLP-1s — the drugs just produce more weight loss.
The “lean mass loss” signal itself is likely overstated due to DXA’s limitations. DXA cannot distinguish skeletal muscle from liver mass, intramuscular fat, glycogen, or extracellular fluid — and Langer et al. found liver mass decreased 20–55% across incretin agents in preclinical models, tracking tightly with body weight while muscle mass barely did.  When function is actually measured, semaglutide reduced muscle cross-sectional area on ultrasound yet grip strength and knee extension were unchanged; STEP 9 showed improved physical function scores despite lean mass changes.  Mass and function are dissociable — and often moving in opposite directions.
The practical answer is clear. The Lundgren NEJM RCT showed that exercise plus liraglutide preserved lean mass and produced 15.7% total weight loss — roughly double the fat reduction of either intervention alone — while neutralizing liraglutide’s resting heart rate increase. A small case series with structured resistance training on semaglutide/tirzepatide showed two of three patients actually gaining lean tissue during major weight loss. The protocol: resistance training 2–3x/week, protein at 1.2–1.6 g/kg adjusted body weight, and functional monitoring (grip strength, gait speed) — built in from the start.
